Medicine

UPenn researchers looked at 15,550 patients admitted to Pa. trauma centers from March 21 to July 31, 2020; 8,170 had been tested for the virus.

What does the brain need to be healthy? Doctors Daniel Monti and Andrew Newberg discuss the latest in brain science and share ways to stay cognitively fit.

Is one J&J COVID-19 vaccine shot enough? Is a mixed vaccine regimen better? Here’s what WHYY’s Health Desk Help Desk found out.

They said that another shot within 12 months could dramatically boost immunity and maybe help ward off the latest worrisome coronavirus mutant.

The bill makes it easier for producers to remove contaminants such as yeast and mold from medical marijuana, to turn it into products that are topical, not to be inhaled.

Health experts say the Pfizer and Moderna COVID-19 vaccines are safe following rare incidents of heart inflammation, and that the benefits of vaccination outweigh the risks.

WHYY’s Health Desk Help Desk answers more questions about the COVID-19 vaccine from people with very specific concerns about its effect and effectiveness.

Why are we falling short of President Biden's 70% vaccination rate target for July 4th? Also, the latest on the Delta variant and how barber shops are becoming vaccine hubs.

A third shop just opened in Center City, while some neighborhoods don’t have any.

An on-again/off-again/on-again exemption means no special training is required for medical professionals to prescribe buprenorphine to up to 30 patients each.

Long COVID effects are still unexplainable, and a cure is elusive. Some hope the vaccine will help. But doctors say that depends on the symptoms.

Former Philadelphia Mayor Michael Nutter on his prostate cancer, restrictive voting bills in Pa., and the plight of endangered red knots migrating through Delaware Bay.

What is the risk, if any, while someone is expecting? WHYY’s Health Desk Help Desk looked into what the research is showing.

U.S. regulators are allowing the release of 10 million doses of Johnson & Johnson's COVID-19 vaccine from a troubled Baltimore factory, but many other doses can't be used.

FDA approved the controversial Alzheimer’s drug aducanumab. We'll talk with Penn Memory Center's Dr. Jason Karlawish about the decision and the state of Alzheimer's research.